# A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

> **NCT01060254** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 31 (actual)

## Conditions studied

- Cystitis, Interstitial
- Urologic Diseases
- Urinary Bladder Diseases
- Cystitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-42160443

## Key facts

- **NCT ID:** NCT01060254
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-06
- **Primary completion:** 2011-06-24
- **Final completion:** 2011-06-24
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Logistic reasons associated with the FDA-imposed clinical hold.
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01060254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01060254, "A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01060254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*